CDC20 and its downstream genes: potential prognosis factors of osteosarcoma
We investigated the microarray data GSE42352 to identify genes that can be used as prognosis factors in osteosarcoma.
Gene Ontology (GO) biological process analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of Cytoscape ClueGo were used in verifying the function of different genes. Realtime-PCR were used to confirm the microarray results. 83 patient samples were collected and underwent Kaplan–Meier survival analysis and multivariate analysis to predict the prospect of genes using as prognosis factors.
After analyzing the microarray data GSE42352, mitosis metaphase to anaphase-related genes CDC20, securin, cyclin A2 and cyclin B2 were found to be overexpressed in osteosarcoma cell lines. Kaplan–Meier survival analysis showed that overexpression of these genes can predict poor prognosis outcomes in osteosarcoma patients. Furthermore, any combination of the four genes seems to be more effective in predicting osteosarcoma outcomes than any of these genes alone.
CDC20 and its downstream substracts securin, cyclin A2 and cyclin B2 are good factors that can predict prognosis outcomes in osteosarcoma. Any two combination of these four genes are more effective to be used as osteosarcoma prognosis factors.
KeywordsOsteosarcoma Cell cycle CDC20 Prognosis
This work was supported by Grants from National Natural Science Foundation of China (nos. 81702943, 81602356), Medical Science and Technology Research Foundation of Guangdong, China (no. A2018543).
Compliance with ethical standards
Conflict of interest
The authors report no conflict of interest.
- 1.Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ(R)) (2002) Health Professional Version, in PDQ Cancer Information Summaries. Bethesda (MD).Google Scholar